Pharma’s outlook in 2026: Smoother sailing ahead?

Pharma’s outlook in 2026: Smoother sailing ahead?

After a turbulent year, the industry has a clearer picture of its new landscape and how to navigate the challenges and opportunities ahead.

Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector

As the biotech and pharmaceutical industry moves into 2026, multiple forces are converging at once: emerging technologies are approaching pivotal clinical readouts, regulatory and pricing … [Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector Read More » The post [Illustrations] Biopharma Investment Heads Into a 2026 “Settlement Year,” With Clinical Data Set to Reprice the Sector …